乐天医疗CEO前田美波讨论了公司正在进行的3期临床试验、2028年提交FDA申请的目标以及实现美国商业化所需的额外资金。
Rakuten Medical CEO Minami Maeda discusses the company’s ongoing Phase 3 trial, its target of a 2028 FDA submission and the additional capital needed to reach U.S. commercialization.
他还概述了全球扩张计划，包括潜在的公开或私募融资以及战略合作伙伴关系。
He also outlines plans for global expansion, including potential public or private funding and strategic partnerships.